Literature DB >> 11318764

The role of therapeutic drug monitoring in treatment of HIV infection.

D J Back1, S H Khoo, S E Gibbons, C Merry.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11318764      PMCID： PMC2014453          DOI： 10.1046/j.1365-2125.2001.01380.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  30 in total

1.  The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.

Authors:  R P van Heeswijk; A I Veldkamp; R M Hoetelmans; J W Mulder; G Schreij; A Hsu; J M Lange; J H Beijnen; P L Meenhorst
Journal:  AIDS       Date:  1999-10-01       Impact factor: 4.177

2.  Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.

Authors:  D V Havlir; N S Hellmann; C J Petropoulos; J M Whitcomb; A C Collier; M S Hirsch; P Tebas; J P Sommadossi; D D Richman
Journal:  JAMA       Date:  2000-01-12       Impact factor: 56.272

3.  Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

Authors:  D Descamps; P Flandre; V Calvez; G Peytavin; V Meiffredy; G Collin; C Delaugerre; S Robert-Delmas; B Bazin; J P Aboulker; G Pialoux; F Raffi; F Brun-Vézinet
Journal:  JAMA       Date:  2000-01-12       Impact factor: 56.272

4.  Variability in trough plasma saquinavir concentrations in HIV patients--a case for therapeutic drug monitoring.

Authors:  M G Barry; C Merry; J Lloyd; K Halifax; P Carey; F Mulcahy; D J Back
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

5.  Improved tolerability of ritonavir derived from pharmacokinetic principles.

Authors:  C Merry; M Barry; S Gibbons; F Mulcahy; D Back
Journal:  Br J Clin Pharmacol       Date:  1996-12       Impact factor: 4.335

Review 6.  Ritonavir.

Authors:  A P Lea; D Faulds
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

7.  The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1.

Authors:  K H Moore; J E Barrett; S Shaw; G E Pakes; R Churchus; A Kapoor; J Lloyd; M G Barry; D Back
Journal:  AIDS       Date:  1999-11-12       Impact factor: 4.177

8.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

9.  The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

Authors:  R B Kim; M F Fromm; C Wandel; B Leake; A J Wood; D M Roden; G R Wilkinson
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

10.  HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

Authors:  C G Lee; M M Gottesman; C O Cardarelli; M Ramachandra; K T Jeang; S V Ambudkar; I Pastan; S Dey
Journal:  Biochemistry       Date:  1998-03-17       Impact factor: 3.162
View more
  11 in total

1.  Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study.

Authors:  Rolf P G van Heeswijk; James W T Cohen Stuart; David M Burger; Jos H Beijnen; Jan C C Borleffs; Richard M W Hoetelmans
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

2.  Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy.

Authors:  Rieneke M E van Praag; Elisabeth C M van Weert; Rolf P G van Heeswijk; Xiao-Jian Zhou; Jean-Pierre Sommadossi; Suzanne Jurriaans; Joep M A Lange; Richard M W Hoetelmans; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

3.  Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.

Authors:  X Panhard; C Goujard; M Legrand; A M Taburet; B Diquet; F Mentré
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

4.  Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients.

Authors:  Leonardo Calza; Laura Mosca; Daria Pocaterra; Benedetta Piergentili; Vincenzo Colangeli; Roberto Manfredi; Annalisa Erario; Gabriele Grossi; Gabriella Verucchi; Pierluigi Viale
Journal:  Eur J Clin Pharmacol       Date:  2010-09-28       Impact factor: 2.953

5.  Differential bidirectional transfer of indinavir in the isolated perfused human placenta.

Authors:  Sreeja Sudhakaran; Hany Ghabrial; Roger L Nation; David C M Kong; Neil M Gude; Peter W Angus; Craig R Rayner
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

6.  Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients.

Authors:  Julio S G Montaner; Malte Schutz; Robert Schwartz; Dushyantha T Jayaweera; Alfred F Burnside; Sharon Walmsley; Michael S Saag
Journal:  MedGenMed       Date:  2006-05-10

Review 7.  Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?

Authors:  Rob E Aarnoutse; Jonathan M Schapiro; Charles A B Boucher; Yechiel A Hekster; David M Burger
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Therapeutic Drug Monitoring of Anti-infective Drugs: Implementation Strategies for 3 Different Scenarios.

Authors:  Hannah Yejin Kim; Kenneth C Byashalira; Scott K Heysell; Anne-Grete Märtson; Stellah G Mpagama; Prakruti Rao; Marieke G G Sturkenboom; Jan-Willem C Alffenaar
Journal:  Ther Drug Monit       Date:  2022-02-01       Impact factor: 3.118

9.  The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.

Authors:  Marta Boffito; Patrick G Hoggard; Helen E Reynolds; Stefano Bonora; E Rhiannon Meaden; Alessandro Sinicco; Giovanni Di Perri; David J Back
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

10.  Determination of ddATP levels in human immunodeficiency virus-infected patients treated with dideoxyinosine.

Authors:  Cecile Le Saint; Raphael Terreux; Daniele Duval; Jacques Durant; Helene Ettesse; Pierre Dellamonica; Roger Guedj; Jean Pierre Vincent; Anny Cupo
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.